论文信息 - Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera - 字舞流文

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera

T. Barbui | G. Tognoni | A. Patriarca | P. Guglielmelli | A. Vannucchi | C. Musolino | V. De Stefano | F. Pane | F. Ciceri | E. Rumi | N. Vianelli | A. Rambaldi | G. Carli | M. Bonifacio | E. Rossi | A. Iurlo | G. Benevolo | A. Ricco | S. Siragusa | L. Scaffidi | G. G. Loscocco | A. Carobbio | S. Betti | M. Finazzi | A. Ghirardi | M. Bellini | A. Masciulli | F. Palandri | D. Rapezzi | E. Cacciola | C. Mannarelli | N. Cascavilla | F. Lunghi | B. Mora | C. Bucelli | M. Caramella | F. Gesullo | Greta Carioli

[1] S. Gupta,et al. Real-world treatments and thrombotic events in polycythemia vera patients in the USA , 2023, Annals of Hematology.

[2] A. Mead,et al. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia , 2022, Blood.

[3] Raúl Pérez,et al. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera , 2021, Annals of Hematology.

[4] T. Barbui,et al. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views , 2021, Leukemia.

[5] Michael A Proschan,et al. The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design , 2020, BMJ.

[6] E. Papaemmanuil,et al. Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea. , 2019, Blood.

[7] T. Barbui,et al. Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis , 2019, Haematologica.

[8] T. Barbui,et al. Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera , 2018, Leukemia.

[9] R. Mesa,et al. Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States , 2018, Clinical lymphoma, myeloma & leukemia.

[10] M. Griesshammer,et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet , 2018, Leukemia.

[11] T. Barbui,et al. A reappraisal of the benefit‐risk profile of hydroxyurea in polycythemia vera: A propensity‐matched study , 2017, American journal of hematology.

[12] S. Giraudier,et al. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone , 2016, Leukemia.

[13] R. Greil,et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. , 2015, Blood.

[14] T. Barbui,et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. , 2015, Blood.

[15] T. Barbui,et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. , 2014, Blood.

[16] M. Cazzola,et al. Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.

[17] T. Barbui,et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. , 2013, Blood.

[18] T. Barbui,et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. , 2011, Blood.